Article
Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis.
The pharmacogenomics journal - 1 Oct 2015
Verbelen M, Collier D A, Cohen D, MacCabe J H, Lewis C M
Abstract excerpt
Clozapine is the only evidence-based therapy for treatment-resistant schizophrenia, but it induces agranulocytosis, a rare but potentially fatal haematological adverse reaction, in less than 1% of users. To improve safety, the drug is subject to mandatory haematological monitoring throughout the course of treatment, which is burdensome for the patient and one of the main reasons clozapine is underused. Therefore,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
